Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy
Open Access
- 4 November 2016
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (51) , 84965-84980
Abstract
Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacyKeywords
This publication has 54 references indexed in Scilit:
- Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSFGene Therapy, 2011
- Optimizing DC Vaccination by Combination With Oncolytic Adenovirus Coexpressing IL-12 and GM-CSFMolecular Therapy, 2011
- Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18RαGene Therapy, 2011
- Therapeutic and Tumor-specific Immunity Induced by Combination of Dendritic Cells and Oncolytic Adenovirus Expressing IL-12 and 4-1BBLMolecular Therapy, 2010
- Use of tumour-responsive T cells as cancer treatmentThe Lancet, 2009
- Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibitionGene Therapy, 2008
- Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinomaCancer Science, 2006
- Cytokines in cancer immunity and immunotherapyImmunological Reviews, 2004
- Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin’s Lymphoma and Hodgkin’s DiseaseClinical Cancer Research, 2004
- Positive and Negative Selection of T CellsAnnual Review of Immunology, 2003